XPA tumor variants lead to defects in NER that sensitize cells to cisplatin.

Alexandra M BleeKaitlyn S GallagherHyun-Suk KimMihyun KimChristina R TrollAreetha D'SouzaJiyoung ParkP Drew NeuferOrlando D SchärerWalter J Chazin

Published in: bioRxiv : the preprint server for biology (2023)

A destabilized, readily degraded tumor variant identified in the NER scaffold protein XPA sensitizes cells to cisplatin, suggesting that XPA variants can be used to predict response to chemotherapy.

Keyphrases

induced apoptosis
cell cycle arrest
endoplasmic reticulum stress
copy number
squamous cell carcinoma
cell death
gene expression
small molecule
dna methylation
protein protein
binding protein